Serbia vs Slovenia: Death rate from cancer
Serbia
312.25 deaths per 100,000 people
in 2021
Slovenia
305.17 deaths per 100,000 people
in 2021
Serbia rank
5th
Slovenia rank
8th
Death rate from cancer over time
- Serbia
- Slovenia
How they compare
Serbia currently reports 312.25 deaths per 100,000 people against 305.17 deaths per 100,000 people in Slovenia, a difference of 7.08 deaths per 100,000 people.
The two have swapped places 2 times across 22 shared years of data; in 2000 it was Serbia ahead.
Serbia ranks 5th and Slovenia ranks 8th of 194 countries.
Serbia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Serbia | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 278.04 deaths per 100,000 people | 263.52 deaths per 100,000 people | 14.53 deaths per 100,000 people | Serbia |
| 2010s | 312.44 deaths per 100,000 people | 297.12 deaths per 100,000 people | 15.31 deaths per 100,000 people | Serbia |
| 2020s | 317.29 deaths per 100,000 people | 306.26 deaths per 100,000 people | 11.03 deaths per 100,000 people | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Serbia or Slovenia?
- Serbia, at 312.25 deaths per 100,000 people against 305.17 deaths per 100,000 people in Slovenia as of 2021.
- What is the difference in death rate from cancer between Serbia and Slovenia?
- 7.08 deaths per 100,000 people, with Serbia ahead.
- How many years of comparable data are there for Serbia and Slovenia?
- 22 years are reported by both, from 2000 to 2021.
- How do Serbia and Slovenia rank globally for death rate from cancer?
- Serbia ranks 5th and Slovenia ranks 8th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.